

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number  
**WO 2005/080265 A2**

(51) International Patent Classification<sup>7</sup>: **C01B 21/00**

(21) International Application Number:  
PCT/GB2005/000480

(22) International Filing Date: 14 February 2005 (14.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0403696.8 19 February 2004 (19.02.2004) GB

(71) Applicant (*for all designated States except US*): **AVECIA PHARMACEUTICALS LIMITED** [GB/GB]; PO Box 42, Hexagon Tower, Blackley, Manchester M9 8ZS (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ARCHER, Ian, Victor, James** [GB/GB]; 19 Ashville Terrace, Edinburgh EH6 8DD (GB). **HAMILL, Noel, Anthony** [IE/GB]; P.O. Box 521, Leeds Road, Huddersfield, West Yorkshire HD2 1GA (GB).

(74) Agents: **GAIRNS, Raymond, Stevenson** et al.; Avecia Pharmaceuticals limited, Intellectual Property Group, PO Box 42, Hexagon Tower, Blackley, Manchester M9 8ZS (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PROCESS FOR PREPARING LITHIUM AMIDE AND A COMPOSITION OBTAINABLE BY SAID PROCESS

(57) Abstract: There is provided a process for preparing a lithium amide composition in which in a first step lithium metal is brought into contact with ammonia to form lithium bronze and in a second step the lithium bronze is reacted with a 1,3-diene or an arylolefin, such as butadiene, isoprene, piperylene, dimethylbutadiene, hexadiene, styrene, methyl styrene, divinylbenzene, naphthalene or anthracene, in the presence of a solvent wherein the temperature is maintained at or below the boiling point of ammonia. Examples of solvents include pentane, cyclopentane, hexane, heptane, octane, cyclohexane, toluene, xylene, cumene, ethyl benzene, tetraline, diethyl ether, tetrahydrofuran (THF), 2-methyl-THF, tetrahydropyran, diisopropyl ether, dibutyl ether, dioxan, methyl-tert-butyl ether or glycol ether. Lithium amide compositions obtainable by said process show improved activity, particularly in reactions involving enolate formation.



**WO 2005/080265 A2**